Ivan Maldonado
@mivan_eduardoBreast Medical Oncologist
Similar User
@javiercboj
@AndreaMaliachi
@school_latin
@Lalo_rey_90
@anelcabrera
@maritza_rramos
@Poggio_Fra
@drlopezgalindo
@Ale15326720
@DrMedOnco
@HerediaOncologo
@Antonio_arc95
@anakvalenzuelav
@lopezlemusmd
@dradianaflores
🪡 Threading the Needle in the Haystack: ctDNA Applications in Early and Advanced Breast Cancer 🧬 ➡️ ctDNA is here - use with care❗️ Excellent presentation by @StoverLab @OncoAlert #ASCO24 @OSUCCC_James
Who should you maybe consider for supplemental breast MRI after initial cancer? 🔘non-HR+, particularly TNBC 🔘high initial breast cancer risk 🔘 young age <50 of primary breast cancer 🔘dense breasts which makes mammography less sensitive #bcsm #ASCO24
The longest follow up to date of a metastatic trastuzumab trial: after 20 years from receiving TCH, 10% of the patients included in this phase 2 study was still alive. academic.oup.com/oncolo/advance… How to recognize & increase the rate of long-term survivors? 👉 jamanetwork.com/journals/jamao…
#BestOfASCObyINCan Honrado de participar con colegas, amigos y maestros del Instituto Nacional de Cancerología de México - INCan, en el programa The Best of ASCO 2023, discutiendo los últimos avances y perspectivas en #OncologíaMamaria @PTarantinoMD @anelcabrera
So a great conference and discussion on ADCs. Best of Asco By #INCAn. Thanks so much, @PTarantinoMD @mivan_eduardo @DrMedOnco y Claudia Arce.
Pretty clear after @SABCSSanAntonio and @ASCO meetings that "HER2 low" is not a biological thing. HER2 0 and HER2 low tumors behave the same clinically. Serial testing shows that lots of HER2 1+/2+ are HER2 0 on later testing, or vice versa.
Another excellent discussion at the #ASCO23 oral abstract #BreastCancer session by super @BarbaraPistill2 from @GustaveRoussy 🔝👏🤩🥰🇮🇹 @OncoAlert #ItalianPride
What an excellent discussion!!! Super congrats @StoverLab 👏👏👏👏 🔝🔝🔝🔝🤩🤩🤩🤩 @OncoAlert #ASCO23
FANTASTIC and practice changing trial from the Netherlands, SONIA shows that CDK4/6i in 2nd line are as effective as in 1st line with less Toxicity and cost. This is what happens when you ask right questions and design studies to benefit patients instead of companies. #ASCO23
DB-04 sub-analysis: T-DXd outperformed chemo in HER2-low MBC irrespective of intrinsic subtype, ESR1 status, PIK3CA status and CDK4/6i resistance markers. Highest activity of T-DXd in HER2-enriched (ORR >60%!) #ASCO23
PHERGain beautifully presented by @JavierCortesMD : 80% with preop HP had early PET response, 38% w/ pCR 95.4% iDFS for the HP arm 3 yr iDFS for those pts w/o chemo (n=86) 98.8% Early PET response seems to help de-escalate therapy in early HER2+ disease @OncoAlert #ASCO23
One of my favorite tweets of the year! Can’t wait to see all of the progress in #breastcancer at #ASCO23 this year! #bcsm
Totalmente MOST. @diegoadiazg @AndresFCardonaZ @ogarrieta @DHeredia_onco @LuisLara_M @maritza_rramos #MOST #INCAN #IAOM
Q vergüenza el sesgo, ese informe no tiene ni pies ni cabeza, aquí estamos un grupo humano que da la cara, que ha actuado en procura de los intereses del estado. Sin perjuicio de esto ya hemos solicitado a la CGE que haga el análisis de lo que políticamente se quiere hacer show.
pN1 is the limit of nodal burden to apply RxPONDER criteria and omit chemotherapy in HR+HER2- #breastcancer but… in cN0 disease with upfront #surgery, how many pN2/pN3 patients are really out there?
Excited for this upcoming symposium @AACR on #acceleratedapproval with an outstanding panel of thought leaders in #precisionmedicine! @VivekSubbiah @DianaBradfordMD @sjwhitlock #loriwirth @FDAOncology
📢🥁Just 1 week more for the MAJOR Symposium👉 "Defining Clinical Benefit: Accelerated Approval in Precision Oncology" session in @AACR #AACR22 Moderated by @GautamMehtaMD @FDAOncology Speakers: FDA, patient advocacy, academia & yours truly🎯@tmprowell bit.ly/3JcBFkf
Hoy en la programación de #QuitoActívate, nos acompaña Iván Maldonado, Médico especialista en Oncología, quien nos informará acerca de la vacunación en pacientes oncológicos. Somos #LaRadioDeLaCiudad, Contáctanos :☎️2510 510 o al ☎️2510 511.
United States Trends
- 1. Chargers 56,1 B posts
- 2. Ravens 1.105 posts
- 3. Quentin Johnston 5.781 posts
- 4. Kerr 7.171 posts
- 5. Drake 348 B posts
- 6. #WWERaw 66,6 B posts
- 7. Dayton 3.648 posts
- 8. Lamar 181 B posts
- 9. Canada 408 B posts
- 10. Herbert 19,6 B posts
- 11. Cadeau 9.483 posts
- 12. Derrick Henry 9.316 posts
- 13. Kofi 16,3 B posts
- 14. Seth Trimble N/A
- 15. #BALvsLAC 9.294 posts
- 16. Nets 15,4 B posts
- 17. Ladd 4.820 posts
- 18. Kings 53 B posts
- 19. OG Anunoby 4.843 posts
- 20. Podz N/A
Who to follow
-
Javier Cervantes-Bojalil
@javiercboj -
Andrea Maliachi
@AndreaMaliachi -
Latin American School of Oncology (ELO)
@school_latin -
Eduardo Rey-Torres C
@Lalo_rey_90 -
Paula Cabrera
@anelcabrera -
Maritza Ramos MD
@maritza_rramos -
Francesca Poggio
@Poggio_Fra -
Angel Lopez-Galindo, MD, MHA
@drlopezgalindo -
Ale Salazar
@Ale15326720 -
Carlos Gonzalez
@DrMedOnco -
David Heredia.
@HerediaOncologo -
Antonio García
@Antonio_arc95 -
Ana K. Valenzuela
@anakvalenzuelav -
Mariana Lopez L.
@lopezlemusmd -
Diana Flores
@dradianaflores
Something went wrong.
Something went wrong.